Article
Oncology
Ying-Yi Chen, Kuan-Hsun Lin, Yen-Shou Kuo, Yuan-Ming Tsai, Hsu-Kai Huang, Tsai-Wang Huang
Summary: This study investigated the impact of EGFR-TKI in patients with advanced lung adenocarcinoma treated with various therapeutic strategies. The results showed that TKI with lung cancer salvage surgery is the best therapeutic strategy, leading to significantly longer overall survival and extended duration of TKI usage.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
E. Zhou, Feng Wu, Mengfei Guo, Zhengrong Yin, Yumei Li, Minglei Li, Hui Xia, Jingjing Deng, Guanghai Yang, Yang Jin
Summary: The established ERS in this study can predict a poor prognosis for LUAD patients and has the potential to predict drug responses.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson
Summary: This review critically analyzes the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.
Article
Oncology
Chenyue Dai, Zeming Ma, Jiahui Si, Guo An, Wenlong Zhang, Shaolei Li, Yuanyuan Ma
Summary: The study demonstrated that inhibition of circ7312 can decrease osimertinib resistance by regulating the miR-764/MAPK1 axis and promoting pyroptosis and apoptosis, providing a novel target for osimertinib resistance therapy.
Article
Biochemistry & Molecular Biology
Anastasios Gkountakos, Giovanni Centonze, Emanuele Vita, Lorenzo Belluomini, Michele Milella, Emilio Bria, Massimo Milione, Aldo Scarpa, Michele Simbolo
Summary: The use of EGFR tyrosine kinase inhibitors has significantly improved the management of lung adenocarcinoma, but long-term clinical benefit is compromised by multiple resistance mechanisms, including metabolic remodeling. Metabolic pathways and metabolites have been implicated in resistance to EGFR TKIs and they may also serve as predictive biomarkers. Additionally, targeting nutrient dependencies may offer a potential strategy to counteract resistance.
Article
Oncology
Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
Summary: This study investigated 363 patients with advanced lung adenocarcinoma harboring EGFR mutations and evaluated the efficacy of afatinib, erlotinib, and gefitinib according to mutation type. E19del and L858R mutations were associated with superior progression-free survival and overall survival compared to uncommon mutations. Afatinib showed significantly longer progression-free survival across all EGFR mutation types.
Article
Chemistry, Multidisciplinary
Paolo Zucchiatti, Giovanni Birarda, Andrea Cerea, Marta S. Semrau, Aliaksandr Hubarevich, Paola Storici, Francesco De Angelis, Andrea Toma, Lisa Vaccari
Summary: This study demonstrates the potential of SEIRA microscopy in detecting subtle secondary structure modifications associated with the binding of Lapatinib to EGFR. By optimizing techniques and data analysis, the researchers successfully identified secondary structure modifications in EGFR related to a few amino acids.
Article
Oncology
Qing Chang, Huiping Qiang, Jialin Qian, Yuqiong Lei, Jiahuan Lu, Hui Feng, Yiming Zhao, Baohui Han, Yanwei Zhang, Tianqing Chu
Summary: For advanced Chinese female lung SCC patients with EGFR positive mutations, targeted therapy could confer longer progression-free survival (PFS) and overall survival (OS) than chemotherapy, but the survival was similar with patients who were negative EGFR mutations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Xuelin Zhang, Tengfei Ye, Mingdong Li, Hongwang Yan, Hui Lin, Hongsheng Lu, Zecheng Qi, Haihui Sheng, Chunya He
Summary: SNPs in inflammation genes were associated with the prognosis of NSCLC patients treated with EGFR-TKIs. Three SNPs were significantly associated with worse PFS, and five SNPs were significantly associated with worse OS. High and intermediate GRSs were associated with worse PFS, and high GRSs were associated with shorter survival time for OS. Furthermore, IL15, IL17RA, AGER, MIF, and TNFRSF1A were dysregulated in LUAD. There was a difference in the expression level of TNFRSF1A between EGFR wildtype and EGFR-mutant LUAD. Low AGER expression and high TNFRSF1A expression were significantly associated with worse PFS in LUAD. Additionally, low IL17RA and AGER expression, and high MIF and TNFRSF1A expression were significantly associated with worse OS in LUAD.
FRONTIERS IN ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Alberto Servetto, Daniela Esposito, Roberto Ferrara, Diego Signorelli, Stefania Belli, Fabiana Napolitano, Antonio Santaniello, Paola Ciciola, Luigi Formisano, Roberto Bianco
Summary: The RET oncogene is an important therapeutic target in solid malignancies, especially in thyroid cancer and non-small cell lung cancer (NSCLC). Tumors harboring RET fusion genes are particularly sensitive to RET tyrosine kinase inhibitors and exhibit distinct clinical and molecular features compared to RET fusion-negative tumors.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Oncology
Keunchil Park, Pasi A. Janne, Dong-Wan Kim, Ji-Youn Han, Ming-Fang Wu, Jong-Seok Lee, Jin-Hyoung Kang, Dae Ho Lee, Byoung Chul Cho, Chong-Jen Yu, Yong Kek Pang, Enriqueta Felip, Hyunjin Kim, Eunhye Baek, Young Su Noh
Summary: Olmutinib demonstrates meaningful clinical activity and a manageable safety profile in patients with T790M-positive non-small cell lung cancer.
Article
Oncology
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, Suey-Haur Lee, Li-Chung Chiu, Chiao-En Wu, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Ho-Wen Ko, Chin-Chou Wang, Cheng-Ta Yang
Summary: This study analyzed the outcomes of advanced EGFR-mutated non-small cell lung cancer patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-TKIs. The majority of resistance to first-line therapy was associated with the T790M mutation. Sequential osimertinib treatment in patients with positive secondary T790M mutation showed better outcomes.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Michael J. Grant, Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz, Andrew J. Piper-Valillo, Zofia Piotrowska, Christina Falcon, Helena A. Yu, Charu Aggarwal, Dylan Scholes, Tejas Patil, Christina Nguyen, Manali Phadke, Fang -Yong Li, Joel Neal, Mark A. Lemmon, Zenta Walther, Katerina Politi, Sarah B. Goldberg
Summary: The drug osimertinib has reduced effectiveness in treating the uncommon EGFR mutation ex19del L747_A750>P compared to the common mutation E746_A750del in non-small cell lung cancer patients. The clinical efficacy of osimertinib in treating tumors with L747_A750>P and other uncommon ex19dels is not known.
CLINICAL CANCER RESEARCH
(2023)
Article
Health Care Sciences & Services
Bee-Song Chang, Tai-Chu Peng, Yi-Feng Wu, Tsung-Cheng Hsieh, Chun-Hou Huang
Summary: This study found predictive factors in toxicity and survival for EGFR-mutated lung adenocarcinoma patients receiving first-line TKI treatment, including high platelet-to-lymphocyte ratio, hypoalbuminemia, age, body mass index, EGFR mutation type, and various blood cell ratios. These factors could help improve risk stratification and individualized treatment strategies for these patients.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Medicine, General & Internal
Yuman Yu, Yuehong Wang, Linying Wu, Xuanli Xu, Hua Zhou, Qing Wang, Jianying Zhou
Summary: The study evaluated the efficacy of EGFR-TKIs plus bevacizumab in advanced non-squamous EGFR-mutated NSCLC patients with gradual progression, showing that the treatment was well-tolerated and promising. Patients with high baseline serum VEGF levels had better PFS2 than those with low baseline levels.